These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 34016077)

  • 41. Clinical, Pathological, and Molecular Characteristics Correlating to the Occurrence of Radioiodine Refractory Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis.
    Luo Y; Jiang H; Xu W; Wang X; Ma B; Liao T; Wang Y
    Front Oncol; 2020; 10():549882. PubMed ID: 33117686
    [No Abstract]   [Full Text] [Related]  

  • 42. Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).
    Capdevila J; Trigo JM; Aller J; Manzano JL; Adrián SG; Llopis CZ; Reig Ò; Bohn U; Cajal TRY; Duran-Poveda M; Astorga BG; López-Alfonso A; Martínez JM; Porras I; Reina JJ; Palacios N; Grande E; Cillán E; Matos I; Grau JJ
    Eur J Endocrinol; 2017 Oct; 177(4):309-317. PubMed ID: 28687563
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement.
    Sabet A; Khalaf F; Yong-Hing CJ; Sabet A; Haslerud T; Ahmadzadehfar H; Guhlke S; Grünwald F; Biersack HJ; Ezziddin S
    Nuklearmedizin; 2014; 53(2):54-9. PubMed ID: 24777355
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nephrotoxicity after PRRT - still a serious clinical problem? Renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATATE and 90Y/177Lu-DOTATATE.
    Kunikowska J; Królicki L; Sowa-Staszczak A; Pawlak D; Hubalewska-Dydejczyk A; Mikołajczak R
    Endokrynol Pol; 2013; 64(1):13-20. PubMed ID: 23450442
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 'Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis'.
    Satapathy S; Mittal BR; Bhansali A
    Clin Endocrinol (Oxf); 2019 Dec; 91(6):718-727. PubMed ID: 31569282
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
    de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
    J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Peptide Receptor Radionuclide Therapy in Thyroid Cancer.
    Gubbi S; Koch CA; Klubo-Gwiezdzinska J
    Front Endocrinol (Lausanne); 2022; 13():896287. PubMed ID: 35712243
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Overview of Development and Formulation of ¹⁷⁷Lu-DOTA-TATE for PRRT.
    Breeman WA; Chan HS; de Zanger RM; Konijnenberg MK; de Blois E
    Curr Radiopharm; 2016; 9(1):8-18. PubMed ID: 25771369
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Theranostics of Thyroid Cancer.
    Giovanella L; Tuncel M; Aghaee A; Campenni A; De Virgilio A; Petranović Ovčariček P
    Semin Nucl Med; 2024 Jul; 54(4):470-487. PubMed ID: 38503602
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.
    Severi S; Sansovini M; Ianniello A; Bodei L; Nicolini S; Ibrahim T; Di Iorio V; D'Errico V; Caroli P; Monti M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1955-63. PubMed ID: 26112388
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.
    Yang X; Li J; Li X; Liang Z; Gao W; Liang J; Cheng S; Lin Y
    J Nucl Med; 2017 Feb; 58(2):258-265. PubMed ID: 27493271
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis.
    Cheng W; Ma C; Fu H; Li J; Chen S; Wu S; Wang H
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1353-60. PubMed ID: 23436920
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
    Jarzab B; Handkiewicz-Junak D; Wloch J
    Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The efficacy of
    Zhang J; Song Q; Cai L; Xie Y; Chen Y
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1533-1543. PubMed ID: 32281025
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients.
    Jarzab B; Handkiewicz-Junak D; Roskosz J; Puch Z; Wygoda Z; Kukulska A; Jurecka-Lubieniecka B; Hasse-Lazar K; Turska M; Zajusz A
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1077-86. PubMed ID: 12783219
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lu-177 labelled peptide treatment for radioiodine refractory differentiated thyroid carcinoma.
    Elboğa U; Özkaya M; Sayiner ZA; Çelen YZ
    BMJ Case Rep; 2016 Mar; 2016():. PubMed ID: 26957032
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug therapy alternatives in the treatment of thyroid cancer.
    O'Doherty MJ; Coakley AJ
    Drugs; 1998 Jun; 55(6):801-12. PubMed ID: 9617595
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
    Ranade R; Basu S
    J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma.
    Gubbi S; Al-Jundi M; Del Rivero J; Jha A; Knue M; Zou J; Turkbey B; Carrasquillo JA; Lin E; Pacak K; Klubo-Gwiezdzinska J; Lin FI
    Front Endocrinol (Lausanne); 2020; 11():587065. PubMed ID: 33551992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.